Latest Production Milestones News

Manuka Resources has received its first gold revenue after restarting processing at the Wonawinta plant in New South Wales. The company expects fortnightly gold revenue of A$3.0 million to A$4.0 million through the end of 2026, although sales remain dependent on the plant reaching steady state.

Axel REE has more than doubled the Woolrich resource to 264.6 million tonnes and delivered its first Indicated classification at the Brazilian rare earths project. The upgrade comes as the loss-making explorer prepares a controlled in-situ recovery field validation program, with A$5.73 million in cash at year-end.

Emu NL has moved from geological validation at Fiery Creek into a larger drilling campaign at its Yataga Valley copper project, after ending FY2026 with $3.15 million in cash. The progress comes with a material warning: the auditor said the company’s ability to continue as a going concern depends on securing further capital.

St George Mining’s Araxá project now boasts a 111.2Mt rare earths resource after a major post-year-end upgrade, alongside 630,000 tonnes of contained niobium. The 2026 annual report shows a company moving rapidly towards development, but still without an ore reserve, mine design or production decision.

Meeka Metals has secured $40 million after costs through a two-tranche institutional placement priced at $0.10 a share, giving the gold producer fresh funding for Turnberry, Mt Holland and exploration. The capital raise comes as provisional September-quarter gold recovery reached 7,000 to 7,500 ounces and the company expects roughly $50 million in cash after the first tranche.

Nelson Resources has made Gold Point the centrepiece of its exploration strategy, with underground drilling underway in Nevada and exploration assets rising to A$2.81 million. The push came alongside a wider A$1.17 million FY2026 loss, A$2.10 million in cash and continued reliance on equity funding.

Micro-X has told ASX it is unaware of any undisclosed information explaining the sharp move in its shares, which rose from $0.030 to $0.045 during 23 September trading. The company pointed to elevated volumes, earlier institutional selling and chairman Patrick O’Brien’s purchase of 1.36 million shares.

BluGlass has agreed an A$8.0 million R&D-backed loan with Rockford, refinancing its existing Radium facility and adding about A$5.5 million of liquidity. The funding gives the laser developer more room to scale, but carries a 16.5% interest rate and repayment obligations tied to future tax refunds.

Firebrick Pharma has received a $293,000 R&D Tax Incentive payment linked to $673,000 of eligible development spending on new Nasodine products. The non-dilutive cash arrives as the company broadens its product range and pursues approvals in additional markets.

OD6 Metals has transformed its portfolio with the completed acquisition of Nevada’s Quinn Fluorspar Project, but the strategic expansion comes alongside a larger loss, ongoing funding needs and substantial permitting risk. The company is now targeting drilling and a maiden resource at Quinn while advancing laboratory-scale rare earth processing work at Splinter Rock.

ReNerve has converted regulatory approvals into its first commercial NervAlign Nerve Cuff surgeries in Hong Kong and Malaysia, expanding activity to seven jurisdictions. The milestones arrive as FY26 sales climbed 88% to $510,357 and the company builds out its US distribution network.

American Tungsten & Antimony has produced antimony ingot from Arizona-mined material at its Nevada refinery, providing the first physical demonstration of its proposed US mine-to-metal chain. The milestone creates samples for testing and customer qualification, but the underlying asset acquisition remains incomplete and product quality is yet to be disclosed.